Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.60)
# 2,039
Out of 5,172 analysts
52
Total ratings
39.13%
Success rate
6.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Overweight | n/a | $58.89 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $23.33 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $441.16 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.81 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $13.42 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $48.59 | +33.77% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $11.16 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $26.84 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $3.69 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $10.96 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.93 | +154.45% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.27 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $30.07 | -20.19% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.22 | +13,875.16% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $2.13 | +557.28% | 1 | Mar 3, 2021 |
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $58.89
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.33
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $441.16
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.81
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $13.42
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $48.59
Upside: +33.77%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.16
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.84
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.69
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $10.96
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $3.93
Upside: +154.45%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.27
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $30.07
Upside: -20.19%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $3.22
Upside: +13,875.16%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $2.13
Upside: +557.28%